Posted from: Monday, August 01, 2016 - 12:43 PM - Present

Generics to Crestor Authorized

July 19, 2016 –AstraZeneca’s request for an order to block the FDA from approving additional generics to its Crestor® (rosuvastatin) was blocked by a judge. Following this ruling, the FDA approved generics from eight additional manufacturers, some of whom have already begun to ship their version of the medication.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Saturday, July 22, 2017 - 02:38 AM.